Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 EUR | -0.83% | -2.22% | -28.61% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-28.61% | 139M | C- | ||
+14.56% | 9.82B | A- | ||
-5.68% | 5.49B | A- | ||
+10.90% | 4.21B | B- | ||
+16.55% | 3.66B | - | - | |
+44.81% | 2.93B | B | ||
-18.99% | 2.54B | - | ||
-21.20% | 2.35B | C- | ||
+16.38% | 1.85B | D+ | ||
-0.50% | 1.64B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock DBV Technologies - Euronext Paris
- Ratings DBV Technologies